ARI-3037MO

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameARI-3037MO
Drug Alias NameARI-3037-MOARI-3037MO
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHydroxycarboxylic acid receptor 2 agonistsHM74 nicotinic acid GPCR agonists
TargetsHM74 nicotinic acid GPCRHydroxycarboxylic acid receptor 2
Therapy Area/IndicationsHypertriglyceridemiaHyperlipidemiasMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArisaph
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArisaph Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsHypertriglyceridemiaHyperlipidemiasMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A